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ORIGINAL ARTICLE
MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct
enhancer repertoire and target the RUNX1 program in 11q23
acute myeloid leukemia
KHM Prange1, A Mandoli1,3, T Kuznetsova1,3, S-Y Wang1, AM Sotoca1, AE Marneth2, BA van der Reijden2, HG Stunnenberg1
and JHA Martens1
In 11q23 leukemias, the N-terminal part of the mixed lineage leukemia (MLL) gene is fused to460 different partner genes. In order
to deﬁne a core set of MLL rearranged targets, we investigated the genome-wide binding of the MLL-AF9 and MLL-AF4 fusion
proteins and associated epigenetic signatures in acute myeloid leukemia (AML) cell lines THP-1 and MV4-11. We uncovered both
common as well as speciﬁc MLL-AF9 and MLL-AF4 target genes, which were all marked by H3K79me2, H3K27ac and H3K4me3.
Apart from promoter binding, we also identiﬁed MLL-AF9 and MLL-AF4 binding at speciﬁc subsets of non-overlapping active distal
regulatory elements. Despite this differential enhancer binding, MLL-AF9 and MLL-AF4 still direct a common gene program, which
represents part of the RUNX1 gene program and constitutes of CD34+ and monocyte-speciﬁc genes. Comparing these data sets
identiﬁed several zinc ﬁnger transcription factors (TFs) as potential MLL-AF9 co-regulators. Together, these results suggest that MLL
fusions collaborate with speciﬁc subsets of TFs to deregulate the RUNX1 gene program in 11q23 AMLs.
Oncogene advance online publication, 23 January 2017; doi:10.1038/onc.2016.488
INTRODUCTION
Mixed lineage leukemia (MLL), encoded by the lysine (K)-speciﬁc
methyl transferase 2A (KMT2A) gene at 11q23, is a H3K4me3-
depositing protein active during early development. MLL rear-
ranged (MLLr) leukemias are responsible for about 10% of all
acute lymphoblastic and myeloid leukemias (ALL/AML).1 The
N-terminal CXXC-domain containing DNA-binding part of the MLL
gene can, by genomic translocation, be fused to 460 different
fusion partners.2 The two most common fusion partners, AF9
(MLLT3) and AF4 (AFF1), are found in 30% of MLLr AML and 66%
of MLLr ALL cases, respectively.3
The most prevalent fusion partners (including AF9 and AF4) are
present in the super elongation complex (SEC), therefore leading
to a general MLLr mechanism of action despite being composed
of different proteins.4,5 The SEC normally binds to RNA polymerase
II and facilitates transcriptional elongation. In MLLr leukemias, the
SEC is tethered to the DNA-binding domain of MLL via the fusion
partner, leading to aberrant transcription of MLL target genes.
Next to that, AF9 as well as other fusion partners such as ENL,
AF10 and AF17 are present in the DOT1L complex (DOTCOM). This
deposits H3K79me2 on actively transcribed genes, leading to
aberrant H3K79me2 deposition in these subsets of MLLr-induced
leukemias.6–8 As such, a promising avenue for treatment of MLLr-
induced leukemia is inhibition of DOT1L.9,10
Furthermore, AMLs in general and MLLr leukemia in particular
have been shown to be sensitive to inhibition of BET family proteins
such as BRD4, which regulate transcription elongation via P-TEFb at
promoters and enhancers.11–14 MLL fusion proteins have also been
shown to interfere with RUNX115–17 and modulate PU.1 via its distal
regulatory elements.18 Moreover, MLLr and other AMLs are sensitive
to inhibition of mediator kinases,19 linking modulation of distal
regulatory elements to execution of the MLLr leukemic program.
Thus far, genome-wide maps of MLL binding are only available
in mouse models of AML,7 human ALL20–22 and of MLL-AF6 in the
human AML cell line ML-2.23 No reports to date have described
genome-wide MLL-AF9 and -AF4 binding in human AML.
Here we set out to investigate the molecular mechanisms and
targets of MLLr-induced AML. For this, we characterized the
genome-wide binding, epigenetic signature and gene expression
program of wild-type (WT) MLL, MLL-AF9 and MLL-AF4 in human
AML cells. We show that MLL fusion proteins bind in a ‘broad’
mode elongating over the gene body as well as in a ‘sharp’ mode
stalled on the transcription start site (TSS), in addition to non-
genic elements, such as distal enhancers. We show that MLL-AF9
and MLL-AF4 share only a subset of target genes, yet show
enrichment for the same pathways in both the shared as well as
the MLL-AF9- and MLL-AF4-speciﬁc gene sets. These target genes
are marked by H3K79me2, H3K4me3 and H3K27ac enrichment as
well as by RUNX1 occupancy and constitute a mixture of CD34+
and monocyte-expressed gene sets. Together these results
suggest that, in MLLr AML, the RUNX1-mediated progenitor to
monocyte differentiation program is deregulated.
RESULTS
MLL fusions and WT MLL show a broad and sharp binding mode
To investigate the binding sites of MLL-AF9, we used a substrain of
THP-1 cells that express both WT MLL as well as MLL-AF9 but not
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WT AF9 (Figures 1a and b, Supplementary Figure S1A). Using
antibodies against the N-terminus of MLL-1 (ab1542/ab1547) and
the C-terminus of AF9 (ab1327/ab1474) (Figure 1a) in chromatin
immunoprecipitation (ChIP)-qPCR (quantitative PCR) showed
enrichment for the canonical HOXA MLL fusion target region in
THP-1 cells (Figure 1c), while HOXA7 and MEIS1 were, in contrast
to expectations,24–26 not enriched. Western analysis against MLL
and AF9 using our antibodies yielded no results (data not shown),
suggesting that our antibodies were of ‘ChIP-seq grade‘ but not of
‘western grade’. Subsequently, we performed ChIP-seq experi-
ments using MLL and AF9 antibodies in THP-1 MLLr cells that
conﬁrmed enrichment on the HOXA locus for both antibodies
(Figure 1d, top). Interestingly, we observed that both MLL and AF9
show not only ‘broad mode’-enriched regions elongating over
gene bodies (Figure 1d, middle), but also ‘sharp mode’-enriched
regions on target promoters and enhancers (Figure 1d, bottom).
Using MACS2 for deﬁning sharp peaks and HOMER for deﬁning
broad regions (see Materials and methods), we identiﬁed 16 099
unﬁltered MLL occupied regions in THP-1 cells (Supplementary
Table S1). Of these, 8217 were of ‘broad mode’ (mean length
~ 12 kb) and 7882 of ‘sharp mode’ (mean length ~ 4.6 kb)
(Figure 1e, left). Analysis of the genomic distribution revealed
that the ‘broad mode’ peaks cover more TSS regions (Figure 1e,
right), while the ‘sharp mode’ peaks seem to occur in intergenic
regions more often.
As AF9 was not expressed from its endogenous locus in this
substrain of THP-1 cells (Figure 1b, Supplementary Figure S1A), we
deﬁned MLL-AF9-binding peaks as those MLL-binding sites that
show a high AF9 signal, and MLL WT-binding events as those
that show a low AF9 signal (Figure 1f). This distilled our list of
MLL-occupied regions down to 1613 high-conﬁdence MLL-AF9-
fusion-binding sites, including known AML and MLLr targets such
as HOXA9, CDK6, MYB, MYC, JMJD1C, FOXP2, FLI1, RUNX1, PBX3,
BCL2 and BRD4, as well as 439 high-conﬁdence MLL WT-binding
sites (Supplementary Table S1). In all, 84% of these MLL-AF9-
binding sites are ‘broad mode’, versus 58% of WT MLL-binding
sites (Figure 1g, left), and they occupy more TSS regions as
compared with WT MLL (Figure 1g, right).
As MEIS1 occupancy and expression is near universal for all
MLL-fusion-induced AML and ALL,27,28 we investigated the MEIS1
locus in THP-1 cells using our genome-wide data (Supplementary
Figure S1B). This corroborated our ChIP-qPCR ﬁnding that MEIS1 is
not bound by MLL-AF9 and not expressed in THP-1 cells, as it is
marked only by H3K4me3 at its promoter but not by MLL, AF9,
H3K27ac or H3K79me2. MEIS1 expression in MLL-fusion-induced
AML has been shown to be especially important for the initial
transformation of the leukemic cells in mouse models.29–32 It is
therefore conceivable that, at some point since the original
establishment of the THP-1 cell line in 1980,33 the locus was
silenced and its role in leukemic maintenance taken over by
another TALE class protein such as, for example, PBX3, which is
expressed and regulated by MLL-AF9 in THP-1 cells.
In order to further validate our ﬁndings, we performed
additional ChIP-seq experiments against MLL (ab1542) and AF9
(ab1474) in one MLL-AF9-positive AML patient and repeated the
MLL ChIP-seq in THP-1 cells with an antibody targeting a different
epitope (ab1547). ChIP-seq signal intensity at our designated
MLL-AF9-binding regions shows a good enrichment in all three
cases (Supplementary Figure S1C). This indicates that our selected
MLL-AF9 targets are not only bound by the fusion protein in the
cell line system but also in more plastic primary cells.
As MLL-fusion-induced leukemia has previously been studied
in various other human and mouse models, for example, Bernt
et al.7 and Guenther et al.,20 we set out to compare our MLL-AF9
target genes with target genes identiﬁed in these studies. We
found a relatively minor overlap of 12–23% between our set and
the various other sets (Figure 1h, Supplementary Table S2),
which was about the same range of overlap found between the
different mouse studies. This indicates that, while a core set of
targets is present in both human and mouse models, mouse
models do not fully recapitulate the situation in human
leukemogenesis.
Epigenetic signature of MLL-AF9 target genes
As MLLr leukemias have been suggested to alter the epigenetic
signature of affected cells, we compared the epigenetic state of
the MLL fusion with WT MLL target genes focusing on H3K4me3,
H3K79me2 and H3K27ac. For this, we took the set of high-
conﬁdence MLL-AF9 and MLL WT binding events overlapping with
RefSeq hg19 genes, identifying 962 MLL-AF9 and 76 MLL
WT target genes, corresponding to 11% and 1% of all expressed
genes (reads per kilobase of exon per million reads mapped
(RPKM)40.5, cutoff based on RPKM distribution), respectively
(Figure 2a). Promoters of MLL-AF9 target genes were marked by
H3K4me3 and H3K27ac, while a H3K79me2 signal on gene bodies
decreasing in the 5′ to 3′ direction was observed (Figures 2b and c
top), indicating that these genes are actively transcribed. A similar
pattern was seen on WT MLL target genes, and a random pool of
expressed genes, albeit with a mildly reduced signal strength for
H3K79me2 (P= 3.79e− 10 and Po2.2e− 16, respectively) (Figure 2c,
middle, bottom). The lower occupancy of H3K79me2 was also
reﬂected by a lower level of gene expression of WT MLL targets as
opposed to MLL-AF9 target genes, as determined by RNA-seq
(Figure 2d). This suggests that fusion target genes are higher
expressed, in concordance with the paradigm that MLLr activates
MLL target genes by aberrant elongation.
Pathway enrichment analysis of MLL-AF9 target genes revealed
a signiﬁcant (Benjamini–Hochberg-adjusted P-valueo1e− 6)
enrichment of immune system, hemostasis and adaptive immune
system pathways (Supplementary Figure S1D, top). MLL WT target
genes, in contrast, only revealed enrichment for the PDGFRB
pathway (Supplementary Figure S1D, bottom), often involved in
translocation events leading to myeloproliferative disorder.34
Motif analysis35 of MLL-AF9 targets revealed enrichment of the
ETS, AP2 and C2H2-Zf family, while the POU family was depleted
over background (Figure 2e, top left). WT MLL target genes were
enriched for motifs recognized by C2H2-Zf and ETS families,
while the NR family was depleted over background (Figure 2e,
top right). Direct comparison of MLL-AF9 and MLL WT targets
Figure 1. Genome-wide binding patterns of MLL and AF9 in THP-1 cells. (a) Schematic representation of MLL, AF9 and MLL-AF9. Antibody
binding locations are indicated with dotted lines, primer regions used in panel (b) with a ﬁlled line. (b) Reverse transcriptase–qPCR
experiments (n= 5) in THP-1 cells with primers against the C and N termini of MLL and AF9 normalized to GAPDH. The N-terminus of AF9 is
not expressed, indicating that there is no WT expression of AF9 in this cell line. ***Po0.001 (Welch’s t-test). (c) ChIP-qPCR experiments using
two anti-MLL-1 and two anti-AF9 antibodies in THP-1 cells and primers for HOXA7, 9, 10 and MEIS1. (d) ChIP-seq overview of MLL and AF9
binding at the HOXA, ZEB2 and CDKN2C loci in THP-1 cells. (e) Classiﬁcation of MLL and AF9 binding events in ‘broad’ and ‘sharp’ modes. Left:
boxplot showing dispersion of peak lengths. Right: barplot showing genomic distributions. (f) Classiﬁcation of MLL-AF9 and MLL WT binding
events. Average proﬁles showing ChIP-seq signal intensities for MLL-AF9 and MLL WT binding events in THP-1 cells. (g) Left: Distribution of
MLL-AF9 and MLLWT binding events in the ‘broad’ and ‘sharp’ modes. Right: Genomic distribution of MLL-AF9 and MLLWT binding events in
the ‘broad’ and ‘sharp’ modes. (h) Venn diagram illustrating the overlap between our human (THP-1) MLL-AF9 AML targets, MLL-AF9 targets in
a mouse LSC model (Bernt et al.7) and human MLL-AF4 ALL targets (Guenther et al.20).
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revealed both gene sets as similar in terms of motif enrichment,
except for the NR and AP-2 motif families, which were enriched
in the MLL-AF9 target gene set (Figure 2e, bottom). This
suggests that MLL-AF9-mediated deregulation of NR and AP-2
signaling might be involved in aberrant hematopoietic and
immunological processes.
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Similarities of MLL-AF9 and MLL-AF4 binding patterns
To identify common MLL fusion targets, we expanded our analysis
by including an MLL-AF4-expressing AML. As both MLL-AF9 and
MLL-AF4 are thought to bind to MLL target genes and are linked
to aberrant elongation and transcription of their targets via the
SEC, we set out to assess the subset of MLL target genes
commonly bound by the fusion proteins. First, we created
genome-wide binding proﬁles for MLL, AF4, H3K4me3,
H3K79me2 and H3K27ac, as well as an RNA-seq expression proﬁle
in MV4-11 AML cells expressing the MLL-AF4 fusion protein
(Figure 3a, Supplementary Figure S2A–B). As before, we divided
the unﬁltered MLL targets (28 656) into ‘broad mode’ (18 782) and
‘sharp mode’ (9874), and by rate of AF4 occupancy ﬁltered them
down to fusion (2560) and WT (828) binding events (Figure 3b,
Supplementary Figures S2C and D, Supplementary Table S3),
showing a similar distribution as in THP-1 cells (Supplementary
Figure S2E). Expression of MLL-AF4 target genes (1722, identiﬁed
by overlapping the high-conﬁdence fusion-binding events with
RefSeq hg19 genes) was signiﬁcantly higher than MLL WT genes
(308) (Figure 3c). Epigenetic signatures and pathway enrichments
were also comparable to MLL-AF9 AMLs (Supplementary Figures
S2F–H), suggesting that both MLL-AF9 and MLL-AF4 use similar
Figure 2. Epigenetic signature of MLL target genes. (a) Distribution of expressed genes (RPKM40.5), silent genes, MLL-AF9 and MLLWT target
genes. (b) Overview of AF9, MLL, H3K79me2, H3K27ac and H3K4me3 binding and transcriptional activity at the ZEB2 locus in THP-1 cells.
(c) Average signal of H3K27ac, H3K4me3 and H3K79me2 at MLL-AF9 (top), and MLLWT (middle) target genes, as compared with a random set
of expressed genes (bottom) (d) Expression levels of MLL-AF9 and MLL WT target genes. ***Po0.001 (Welch’s t-test). (e) Motif families
enriched over background in MLL-AF9 target gene promoters (top left), MLL WT target gene promoters (top right) and motif families in
MLL-AF9 target gene promoters enriched over MLL WT target gene promoters (bottom).
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molecular mechanisms to induce leukemia. We also found a
similar overlap with the various other target sets as observed for
MLL-AF9 (Supplementary Figure S2I, Supplementary Table S2).
Comparing the MLL-AF9 and MLL-AF4 target gene sets
(Supplementary Table S4) revealed that a signiﬁcant (P=1.98e−11)
29% (277) of MLL-AF9 target genes are also targeted by MLL-AF4
(Figure 3d, top), including known MLLr targets, such as BCL2,
HOXA9, MYB and BRD4. In contrast, only 3% of WT MLL target
genes found in THP-1 were targeted by WT MLL in MV4-11
(Figure 3d, bottom). Next, we analyzed the activity of these
common MLL fusion and MLL WT target genes versus MLL-AF9-
and -AF4-speciﬁc target genes. Common MLL-AF9 and MLL-AF4
target genes, as well as those speciﬁc for MLL-AF9 and -AF4 show
a comparable level of H3K27ac and H3K4me3 (Figure 3e), while
H3K79me2 is slightly lower in MLL-AF9 AMLs. The presence of
H3K79me2 signal on MLL-AF4 target genes conﬁrms the deposi-
tion of this histone tail mark also on MLL-AF4 targets in AML.22,36
The gene expression levels as determined by RNA-seq are
comparable for shared fusion targets in THP-1 and MV4-11, while
the MLL-AF9- and -AF4-speciﬁc target genes are lower expressed
in MV4-11 and THP-1, respectively, with median RPKM values of 23
and 17 for the MLL-AF9-speciﬁc target genes and 25 and 18 for
the MLL-AF4-speciﬁc target genes, respectively (Figure 3f).
Together, this indicates that the set of shared MLL fusion target
genes might represent a ‘core’ set of targets important for driving
the leukemic potential of both MLL-AF9 and -AF4.
Interplay of MLLr target genes with RUNX1 and CTCF
As RUNX1 is a known factor in several types of translocated AML
and ALL37–40 and has been suggested to be involved in
MLLr leukemias,15,16,41 we investigated RUNX1 DNA-binding in
MLL-fusion-induced AML. Next to that, it was recently shown
that MLL-translocated leukemias are affected by mediator kinase
inhibition.19 The mediator complex42 is associated with regulation
of RNA-polymerase II at promoters and distal regulatory elements.
Cohesin, important for the establishment of promoter-enhancer
interactions, co-localizes with CTCF43 and mediator.44 Cohesin
mutations are prevalent in non-translocated AMLs45 and CTCF is
implicated in T-ALL.46 Therefore, we investigated CTCF binding at
MLL fusion targets, as a proxy for mediator/cohesin binding.
CTCF47 (GSM1335528) and RUNX1 show enrichment on MLL-AF9
target genes, while the signal on WT MLL genes is slightly lower
for RUNX1 and almost absent for CTCF (Figure 4a, Supplementary
Figure S3A). A total of 22% (215) of MLL-AF9 target gene
promoters are occupied by CTCF, versus 11% for MLL WT target
genes. For RUNX1, this overlap is 80% (767) and 61% (46),
respectively (Figure 4b, left). Moreover, RUNX1 co-occupied
MLL-AF9 target genes are higher expressed than MLL-AF9 target
genes without RUNX1 co-occupancy (Figure 4b, right). As RUNX1
binding to MLL-AF4 target genes in MV4-11 cells follows a similar
pattern as discussed for MLL-AF9 in THP-1 cells (Supplementary
Figure S3B), together these results suggest that targeting the
RUNX1 gene program is a common feature of MLLr AMLs.
MLL fusion binding at distal regulatory regions
MLLr leukemias have largely been described to function via
aberrant elongation of MLL target genes. However, as we noticed
a signiﬁcant portion (~25%) of MLL-AF9 and MLL WT peaks
occurring in distal regions (Figure 1g, right), we next set out to
characterize these putative MLL-bound enhancers. Overlapping
distal MLL peaks with H3K27ac peaks yielded 342 MLL-AF9-bound
and 75 MLL WT-bound active enhancers with high H3K27ac and
low H3K4me3 signal (Figure 4c, top and middle, Supplementary
Table S5). Interestingly, while RUNX1 was detected on both MLL-
AF9 and MLL WT enhancer peaks, CTCF and H3K79me2 signals
were speciﬁc for MLL-AF9-bound enhancers (Figure 4c bottom,
Supplementary Figure S4A).
Figure 3. Comparison of MLL-AF4 and MLL-AF9 target genes. (a) Overview of AF4, MLL, H3K79me2, H3K27ac and H3K4me3 binding and
transcriptional activity at the ZEB2 locus in MV4-11 cells. (b) Genomic distribution of MLL-AF4 and MLL WT binding events in the ‘broad’
and ‘sharp’ modes. (c) Expression levels of MLL-AF4 and MLLWT target genes. ***Po0.001 (Welch’s t-test) (d) Distribution of MLL-AF9-speciﬁc
and MLL-AF9 and MLL-AF4 common target genes (top). Distribution of MLLWT target genes in THP-1 and MV4-11 (bottom). (e) Average signal
of H3K4me3, H3K27ac and H3K79me2 on MLL-AF4 and MLL-AF9 common and speciﬁc target genes. (f) Expression level of MLL-AF9 target
genes shared (+) or not shared (− ) by MLL-AF4 in THP-1 and MV4-11 cells (left). Expression level of MLL-AF4 target genes shared (+) or not
shared (− ) by MLL-AF9 in THP-1 and MV4-11 cells (right). ***Po0.001 (Welch’s t-test).
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As MLL-AF9 and MLL WT enhancers occupy both intergenic as
well as intronic regions (Figure 4d, top left), we further
characterized only the set of MLL-bound intergenic enhancers to
prevent mixing gene body and intronic enhancer chromatin
signatures. A higher percentage of MLL-AF9-bound enhancers
(39%) than MLL WT-bound enhancers (12%) was marked by
H3K79me2 (Figure 4d, top right). This might reﬂect that aberrant
deposition of the histone mark by DOT1L tethered to the MLL-AF9
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fusion protein. RUNX1 differences were less striking, while a CTCF
peak is present in 50% of all MLL-AF9-bound intergenic regions,
versus 11% for MLL WT, pointing towards increased interaction
with mediator for the MLL fusion-bound enhancers. Next to that,
MLL-AF9-bound intergenic enhancer regions showed a signiﬁ-
cantly higher expression of enhancer RNA than MLL WT-bound
regions (Figure 4d, bottom left), with MLL-AF9-bound intergenic
regions co-occupied by H3K79me2 showing an even higher
expression (Figure 4d, bottom right). Taken together, these
ﬁndings indicate that MLL-AF9-bound enhancer regions are
epigenetically more activated than their WT counterparts and
might show aberrant H3K79me2 deposition and expression owing
to the binding of the MLL fusion protein.
Next we wondered how distal binding sites identiﬁed in MV4-11
cells for the MLL-AF4 fusion would compare to the MLL-AF9-
bound enhancers, as a difference in distal regulatory elements
could potentially explain the difference in gene expression we
found between the MLL-AF9- and -AF4-speciﬁc target genes
(Figure 3f). MLL-AF4 active distal binding regions were similarly
grouped based on H3K27ac (although average H3K27ac signal
was lower as compared with MLL-AF9 distal regions), MLL and AF4
signals (Supplementary Figure S4B, Supplementary Table S5).
Unlike the MLL fusion target genes, there was virtually no overlap
(2%) between MLL-AF9 and MLL-AF4 enhancers, indicating that
the core set of common target genes might be regulated by a
variable set of regulatory regions in the different MLL fusions.
Interestingly, we observed the same decrease in co-occupancy of
H3K79me2 on MLL-AF4 versus MLL WT intergenic enhancers,
while RUNX1 co-occupancy was slightly higher in the WT set, and
no signiﬁcant difference in enhancer RNA expression between
MLL-AF4 and WT MLL intergenic enhancers was observed
(Supplementary Figure S4C). This could indicate that, as the
epigenetic landscape of MLL-AF9- and MLL-AF4-bound active
enhancers is similar except for a lower H3K27ac signal, transcrip-
tional activity of these elements might be restricted to MLL-AF9-
based leukemia, potentially either as a result of differences in
complex presence (DOTCOM vs SEC) or H3K27ac occupancy.
Next we set out to determine the genes these enhancers are
potentially interacting with. The majority of MLL-fusion-bound
enhancer regions are located between 5 and 500 kb from the
nearest TSS (Supplementary Figures S4D and E). However, as the
TSS closest to an enhancer is not necessarily the one it acts upon,
we reﬁned our list of closest genes by comparison with
topologically associating domain (TAD) data and by including
active genes only. For this, we combined the CTCF-binding data in
THP-1 with TADs in human monocytes as determined by HiC
(TK, S-YW and HGS, in preparation) to get an approximate
distribution of TADs. Subsequently, we linked the MLL-AF9-bound
enhancers to the closest active (H3K27ac marked) gene within the
same TAD, resulting in 247 genes putatively regulated by MLL-
AF9-bound enhancers, including BCL2, PHLPP1, RUNX1 and SPI1
(Supplementary Table S6). We conﬁrmed that our THP-1 TAD list
includes the boundary at the 5′ of the HOXA cluster, as described
in THP-1 cells47 (Figure 4f), and performed further validation using
4C-seq experiments on the promoters of BCL2 and PHLPP1, both
MLL-AF9 target genes identiﬁed in this study, as bait. This allowed
to conﬁrm interactions formed by these promoters with MLL-AF9-
bound active enhancers (Figure 4h).
Interestingly, of the 247 genes regulated by MLL-AF9-occupied
enhancers, 25% (61) are MLL-AF9 promoter/gene body-occupied
genes, which is signiﬁcantly (Po0.0001) more than in a random
selection of genes. Next to that, GSEA (gene set enrichment
analysis) pathway analysis of this set of 247 genes revealed
a strong enrichment for cancer (qo1e− 5), CMYB (qo1e− 5),
AML (qo1e− 4) and immune system (qo1e− 4) pathways
(Figure 4g), providing a strong indication that these genes and
their putative enhancers are indeed implicated in MLL-AF9-
mediated leukemogenesis and/or maintenance.
Expression of MLL-AF9 targets in primary cells
Finally, we compared gene expression of MLL fusion cell lines and
primary AML blasts to CD34+ hematopoietic progenitor cells and
primary human monocytes (Supplementary Table S7). We
established that patient blasts cluster separately from CD34+ cells
and monocytes (Figure 5a), Next we focused on the subset of MLL
fusion target genes and investigated their spread by principle
component (PC) analysis (Figure 5b, Supplementary Table S8). We
found that primary MLL fusion samples and cell lines differ from
monocytes by one principle component (PC1) and from CD34+
cells by another (PC2), which is conﬁrmed by functional analysis of
PC1-associated pathways (Figure 5c, top left) and analysis of the
average RPKM of genes in PC1 in the various cell types, which
revealed a higher spread of expression levels for this subset in
monocytes (Figure 5c, bottom left). Analogous functional analysis
of PC2 revealed enrichment for pathways more associated with
dividing (CD34+) progenitor cells (Figure 5c, top right) and an
average CD34+ RPKM with a higher spread (Figure 5c, bottom
right). Together, this suggests that AML-associated MLL fusions
impose a block during monocyte differentiation.
To identify the transcription factors (TFs) that cooperate with
MLL fusion in driving leukemogenesis, we investigated whether
the expression of 878 TFs associated with the MLL-fusion-enriched
motif families (Figures 2e and 4e, Supplementary Figures S2H and
S4F) is different between MLL-fusion-positive cells, CD34+ cells
and monocytes. We identiﬁed 146 TFs differentially expressed in
one or more cell types (Figure 5d, green dots, Supplementary
Table S9). Subsequently, we ﬁltered these TFs based on an RPKM
cutoff of 5 in at least one sample, similar to that of the MLL-AF9
samples, and a deviation from the mean in the same direction in
at least 2 samples, and clustered the remaining 74 TFs on
expression pattern in monocytes, CD34+ cells and MLL-AF9- and
MLL-AF4-expressing cells, revealing 6 TF clusters (Figure 5e), each
of which is differentially expressed in MLL-AF9 cells as compared
with normal cell types or MLL-AF4-expressing cells and potentially
involved in co-regulating MLL-AF9-binding sites. To conﬁrm this
Figure 4. Characterization of MLL-AF9-bound distal regulatory elements. (a) Average signal of RUNX1 and CTCF on MLL-AF9 and MLL WT
target genes. (b) Rate of co-occupancy of MLL-AF9 and MLL WT target genes by RUNX1 and CTCF (left). Expression level of MLL-AF9 target
genes grouped by RUNX1 co-occupancy. ***Po0.001 (Welch’s t-test) (right). (c) Average signal on MLL-AF9 (left) and MLL WT (right) bound
enhancers for H3K4me3 and H3K27ac (top), MLL and AF9 (middle) and RUNX1, CTCF and H3K79me2 (bottom). (d) Genomic distribution of
MLL-AF9 and MLL WT enhancers (top left). Co-occupancy of MLL-AF9 and MLL WT bound enhancers by CTCF, H3K79me2 and RUNX1
z(top right). Expression levels of MLL-AF9 and MLL WT intergenic enhancers (bottom left). Expression level of MLL-AF9-bound enhancers
grouped by H3K79me2 co-occupancy. *Po0.05 (Welch’s t-test). (e) Motif family enrichment for MLL-AF9-bound enhancers. (f) Overview of
HOXA locus in THP-1 cells showing alignment of AF9, MLL, H3K79me2, H3K4me3, H3K27ac, RUNX1 and RNA expression signal with the HOXA
TAD boundary (gray box). (g) Pathway enrichments of active genes nearest to an MLL-AF9-bound enhancer within the same TAD. (h) Long
range interactions from the BCL2 and PHLPP1 promoters as measured by 4C-seq in THP-1 cells (black bars, qo0.01) aligned with MLL, AF9
and H3K27ac ChIP-seq patterns on MLL-AF9-bound enhancers (gray boxes). Arrows highlight examples of interactions of the baited
promoters with MLL-AF9-bound enhancers.
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speciﬁcity, we compared the clustering results to the expression in
other types of AML (Ley et al.48). This identiﬁed three factors,
ZNF521, ZNF433 and ZNF532, for which expression (Figure 5f) was
increased in MLL-AF9-positive cells only, suggesting that these
collaborate with MLL-AF9 in deregulating gene expression and
driving leukemogenesis and several tumor-suppressing factors,
such as ETV3, NR4A1 and EGR2 whose expression (Figure 5g) is
downregulated in MLLr as well as all other types of AML included
in the analysis. Deregulation of, for example, ZNF521, NR4A1 and
EGR2, has indeed previously been implicated in AML.49–51
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In summary, these results show that MLL fusion target genes
identiﬁed in this study can be divided into a group behaving more
like CD34+ cells and a group behaving more like monocytes.
Similarly, expression of TF family members whose motifs were
enriched under MLL-AF9 and -AF4 target genes and enhancers
can also be classiﬁed as CD34+ like, monocyte like or MLLr speciﬁc.
Disturbance of the normal gene expression patterns of both direct
MLLr targets and co-regulating TFs potentially produces the
leukemogenic phenotype witnessed in MLL-translocated AML.
DISCUSSION
In this study, we investigated the genome-wide binding and
epigenetic signature of MLL-AF9, MLL-AF4 and WT MLL in
AML-derived cell lines carrying the respective MLL fusions.
Enrichment of H3K79me2, H3K27ac and RUNX1 signal was high
on both MLL-AF9 and MLL-AF4 target genes. Enrichment of
H3K79me2 conﬁrms that deposition of this histone modiﬁcation
on aberrantly activated MLL fusion target genes is also a feature of
MLL-AF4-induced AML, as was shown for MLL-AF4 in murine and
human ALL models.22,36 Deposition of H3K79me2 is possibly
deregulated in all MLLr acute leukemias involving a component of
the SEC via indirect association of the SEC with DOT1L via AF9 or
ENL.52,53 However, as H3K79me2 is enriched on all activated genes
in general and not just on aberrantly activated MLL fusion targets,
inhibiting DOT1L function to non-speciﬁcally stop H3K79me2
deposition9,54 may introduce deleterious off-target effects.
Enrichment of H3K27ac on aberrantly activated MLLr target
gene promoters—and BRD4 being an MLLr target—corroborates
the facilitating role of bromodomain proteins in transcription of
MLLr targets,55 as evident from AML susceptibility to BET
inhibition.56 This suggests a positive feedback loop where
transcription of MLLr targets is facilitated by BRD4, and BDRD4
is transcribed because it is an MLLr target.
The large overlap between MLLr and RUNX1-binding sites and
the identiﬁcation of RUNX1 as an MLLr target gene suggests that
MLLr AML deregulates (a subset of) the RUNX1 program,
important for hematopoietic development.57 This is reminiscent
of the way the CBFß-MYH11 oncofusion modulates the expression
of RUNX1 targets37 and AML1-ETO can increase the expression of
a subset of RUNX1 targets.58,59 Together with aberrant expression
of genes such as MYC in most AML subtypes,60,61 this hints at the
existence of a core set of genes, including a subset of the RUNX1
program, that is important for leukemic transformation and
maintenance in translocation-induced AML.
In addition to MLL fusion binding to promoter regions as
expected by the consensus of MLLr acting through aberrant
activation of MLL target genes, we determined a signiﬁcant
number of MLL-fusion-binding sites at active distal regulatory
elements enriched for H3K27ac, H3K79me2 and RUNX1 and in
close proximity to genes enriched for pathways related to
leukemia. In light of this, it seems likely that MLLr does not only
act directly on their target genes but can also modulate
the expression of target genes via distal regulatory elements.
The MLL-AF4- and MLL-AF9-bound enhancers showed almost no
overlap, indicating that each MLLr subtype has a distinct enhancer
repertoire. This is in line with several studies linking differences in
acquired and innate resistance to BET inhibition in various AML
cell lines and different clones to a dynamic or variable enhancer
landscape.12,62
Moreover, MLL-AF9-bound enhancers are enriched for CTCF
binding, which is in line with MLLr AML cells being responsive to
treatment with mediator kinase inhibitors.19 This suggests an
active role for MLL-AF9 in modulating the chromatin conformation
to facilitate target gene expression via interference with the
interplay between CTCF, RAD21 (cohesin) and the mediator
complex.63,64
We extracted an extended set of core MLLr target genes
including known targets such as MYC, RUNX1, BCL2 and CDK6,
which can potentially be used to develop new strategies for
combating MLLr leukemias, for instance, by ﬁne-tuning the
targeting of existing potential treatments, such as inhibition of
DOT1L,7,9,54 BLC2i65 or BET11 to MLL fusion target genes only. Next
to that, the uncovered sets of MLL-AF9- and -AF4-speciﬁc target
genes such as ZNF521 and CDKN2A, respectively, indicate that
each speciﬁc fusion partner also has its own unique binding
signature, which may potentially be exploited against MLLr blasts
with resistance against a more general treatment, such as BET
inhibition.55
Finally, we show that gene expression of MLL-AF9 target genes
can be divided into CD34+-like and monocyte-like groups, thereby
keeping the MLL-AF9-positive leukemic cells in a state between
CD34+ progenitor cells and fully differentiated monocytes. Like-
wise, TFs from families with motifs enriched under MLL fusion
targets can be divided into CD34+-like, monocyte-like and MLLr-
speciﬁc groups, uncovering TFs such as ZNF521 and ZNF433 that
are indirectly involved in the expression or selection of MLLr target
genes and tumor-suppressing TFs such as ETV3 and NR4A1 that
are downregulated in MLLr leukemias. Interestingly, ZNF521 is also
an MLL-AF9 target, suggesting a feed-forward loop of ZNF521 and
the MLL-AF9 leukemic program.
MATERIALS AND METHODS
Cell culture
THP-133 and MV4-1166 cells were routinely cultured in RPMI 1640
supplemented with 10% fetal calf serum and 1% penicillin/streptomycin
at 37 °C in a humidiﬁed incubator with 5% CO2. Mycoplasm status was
determined every 6 months.
Patient samples
Bone marrow samples from MLL-AF9-positive AML patients were collected
at diagnosis. The study was conducted in accordance with the Declaration
of Helsinki and institutional guidelines and regulations (CMO 2013/064).
Patient data are summarized in Table 1.
ChIP and ChIP-seq
Chromatin from cell lines was harvested as described.67 ChIPs were
performed using antibodies against MLL-1, AF9, AF4, RUNX1, H3K4me3,
H3K27ac and H3K79me2 and analyzed by qPCR or sequencing. Relative
occupancy was calculated as fold over background, for which the
promoter of the Myoglobin gene was used.
Figure 5. Gene expression levels of MLL-AF9 patient blasts as compared with CD34+ cells, monocytes and AML blasts. (a) Distance-based
clustering on the expression of all hg19 refSeq genes. (b) PC analysis on the expression of MLL-AF9 target genes. (c) Pathway enrichments for
MLL-AF9 target genes in PC1 (top left) and PC2 (top right). Expression levels of MLL-AF9 target genes in PC1 (bottom left) and PC2 (bottom
right). (d) Distribution of differentially expressed AP2, C2H2-Zf, ETS, NR, POU and T-box TFs. Green dots: Benjamini–Hochberg-adjusted
P-valueo0.01 and fold change 44; orange dots: Benjamini–Hochberg-adjusted P-valueo0.05; red dots: fold change 41. (e) Euclidean
distance clustering of 74 TFs expressed signiﬁcantly different in MLL-AF9 cells versus monocytes, CD34+ and MLL-AF4 cells. (f and g) Mean
RPKM of MLL-AF9 AML high (f) and low (g) expressed TFs in CD34+ cells (n= 3), THP-1 (n= 2), MV4-11 (n= 1), monocytes (n= 3), MLL-AF9 blasts
(n= 5), AML-ETO blasts (CGA, n= 7), CBFß-MYH11 blasts (CGA, n= 11), MLLr blasts (CGA, n= 11), PML-RAR blasts (CGA, n= 16) and other AMLs
(CGA, n= 134).
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Reverse transcriptase–qPCR and RNA-seq
Total RNA was extracted with TRIzol (Invitrogen, Bleiswijk, The Netherlands)
or RNAsol (GenDepot, Barker, TX, USA), treated with DNAse on column
(Qiagen, Venlo, The Netherlands) and analyzed by reverse transcriptase–
qPCR or strand-speciﬁc sequencing.
Illumina high-throughput sequencing
ChIP-seq and RNA-seq libraries were prepared according to the
manufacturer’s instructions (Illumina, Eindhoven, The Netherlands). All
data can be downloaded from the Gene Expression Omnibus GSE79899,
GSM1631708, GSM1704846 and GSM1704847 or through the Blueprint
DCC (http://dcc.blueprint-epigenome.eu/#/home).
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